Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. This story matters for Finance & Markets readers tracking broker. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BrokerNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily broker signal